172 related articles for article (PubMed ID: 9466650)
1. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo.
Cormier JN; Hijazi YM; Abati A; Fetsch P; Bettinotti M; Steinberg SM; Rosenberg SA; Marincola FM
Int J Cancer; 1998 Feb; 75(4):517-24. PubMed ID: 9466650
[TBL] [Abstract][Full Text] [Related]
2. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions.
Marincola FM; Hijazi YM; Fetsch P; Salgaller ML; Rivoltini L; Cormier J; Simonis TB; Duray PH; Herlyn M; Kawakami Y; Rosenberg SA
J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):192-205. PubMed ID: 8811494
[TBL] [Abstract][Full Text] [Related]
3. Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes.
Seiter S; Monsurro V; Nielsen MB; Wang E; Provenzano M; Wunderlich JR; Rosenberg SA; Marincola FM
J Immunother; 2002; 25(3):252-63. PubMed ID: 12000867
[TBL] [Abstract][Full Text] [Related]
4. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
5. Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients.
Xu Y; Theobald V; Sung C; DePalma K; Atwater L; Seiger K; Perricone MA; Richards SM
J Transl Med; 2008 Oct; 6():61. PubMed ID: 18945350
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy.
Cormier JN; Abati A; Fetsch P; Hijazi YM; Rosenberg SA; Marincola FM; Topalian SL
J Immunother; 1998 Jan; 21(1):27-31. PubMed ID: 9456433
[TBL] [Abstract][Full Text] [Related]
7. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.
Kawakami Y; Dang N; Wang X; Tupesis J; Robbins PF; Wang RF; Wunderlich JR; Yannelli JR; Rosenberg SA
J Immunother; 2000 Jan; 23(1):17-27. PubMed ID: 10687134
[TBL] [Abstract][Full Text] [Related]
8. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA
J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734
[TBL] [Abstract][Full Text] [Related]
9. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
[TBL] [Abstract][Full Text] [Related]
10. Laser scanning cytometry evaluation of MART-1, gp100, and HLA-A2 expression in melanoma metastases.
Mocellin S; Fetsch P; Abati A; Phan GQ; Wang E; Provenzano M; Stroncek D; Rosenberg SA; Marincola FM
J Immunother; 2001; 24(6):447-58. PubMed ID: 11759068
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients.
Mandelcorn-Monson RL; Shear NH; Yau E; Sambhara S; Barber BH; Spaner D; DeBenedette MA
J Invest Dermatol; 2003 Sep; 121(3):550-6. PubMed ID: 12925214
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of MART-1 in primary and metastatic melanoma lesions.
Kageshita T; Kawakami Y; Hirai S; Ono T
J Immunother; 1997 Nov; 20(6):460-5. PubMed ID: 9409451
[TBL] [Abstract][Full Text] [Related]
13. Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100.
Skipper JC; Gulden PH; Hendrickson RC; Harthun N; Caldwell JA; Shabanowitz J; Engelhard VH; Hunt DF; Slingluff CL
Int J Cancer; 1999 Aug; 82(5):669-77. PubMed ID: 10417764
[TBL] [Abstract][Full Text] [Related]
14. High frequency of melanoma-associated antigen or HLA class I loss does not correlate with survival in primary melanoma.
Hofbauer GF; Burkhart A; Schüler G; Dummer R; Burg G; Nestle FO
J Immunother; 2004; 27(1):73-8. PubMed ID: 14676635
[TBL] [Abstract][Full Text] [Related]
15. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo.
Jäger E; Ringhoffer M; Karbach J; Arand M; Oesch F; Knuth A
Int J Cancer; 1996 May; 66(4):470-6. PubMed ID: 8635862
[TBL] [Abstract][Full Text] [Related]
16. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma.
Jäger E; Ringhoffer M; Altmannsberger M; Arand M; Karbach J; Jäger D; Oesch F; Knuth A
Int J Cancer; 1997 Apr; 71(2):142-7. PubMed ID: 9139833
[TBL] [Abstract][Full Text] [Related]
17. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
[TBL] [Abstract][Full Text] [Related]
18. Immune selection after antigen-specific immunotherapy of melanoma.
Riker A; Cormier J; Panelli M; Kammula U; Wang E; Abati A; Fetsch P; Lee KH; Steinberg S; Rosenberg S; Marincola F
Surgery; 1999 Aug; 126(2):112-20. PubMed ID: 10455872
[TBL] [Abstract][Full Text] [Related]
19. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy.
Rivoltini L; Loftus DJ; Barracchini K; Arienti F; Mazzocchi A; Biddison WE; Salgaller ML; Appella E; Parmiani G; Marincola FM
J Immunol; 1996 May; 156(10):3882-91. PubMed ID: 8621927
[TBL] [Abstract][Full Text] [Related]
20. Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins.
Kang X; Robbins PF; Fitzgerald EB; Wang R; Rosenberg SA; Kawakami Y
Cancer Res; 1997 Jan; 57(2):202-5. PubMed ID: 9000554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
